Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Panacos jumps after HIV data

PANC gained $0.63 (33%) to $2.52 on Friday after reporting late Thursday preliminary data from

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE